Devicare has been one of the companies invited to the Lessons Learned held by the CataloniaBio and Biocat business association on 29 November in Barcelona to explain its business strategy and the lessons it has learned since it was founded in 2012.

The debate centred on the convergence between the biopharmaceutical and MedTech sectors to contribute innovative and effective solutions to the world’s most prominent diseases. Although these two sectors had experienced parallel lives until a few years ago, the coming together of the two has become a global trend which has awakened the interest of the pharmaceutical industry and investors alike.

Personalised medicine and patient empowerment

The general secretary of CataloniaBio, Melqui Calzado, placed the focus of attention on patients who “more and more request more personalized and empowering assistance. This means that the industry must reach an agreement and adapt to this convergence”.

Devicare is a pioneer in this field. Rosendo Garganta, the company’s founder and CEO, indicated that “we have erased the border between developing medicines, dietary supplements and medical devices”. “People are requesting healthcare solutions and services with real and measurable results” she added “so Devicare disruptively combines biotechnology, medical technology and IT”.

The results until now have been two first-in-class solutions which are now on the market, allowing patients to monitor their own chronic urological disease (Lit-Control®) and their INR if they take oral anticoagulants (Tao-Control®) in a remotely controlled manner. Thanks to the patients’ ability to monitor their own health, they spend fewer days in the hospital, have fewer outpatient and emergency care visits, and also report improvements in their health as world-renowned centres such as the Stanford Patient Education Research Center and the University of Illinois Hospital in Chicago have shown, to cite two examples.

2017 has been a year of domestic and international growth for Devicare with distribution agreements for its products in countries such as Mexico, Colombia, France and the United Kingdom.

We recommend reading the full report on CataloniaBio’s website.